Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 12/20 | 1.00 |
| ▸ | GSK3A | P49840 | 11/20 | 1.00 |
| ▸ | CDK1 | P06493 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 10/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 9/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 1.00 |
| ▸ | STK17B | O94768 | 4/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.74 |
| ▸ | CDK2 | P24941 | 3/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.74 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indirubin-3-Monoxime SCHEMBL29354191 | 0.86 | CDK5R1 (1.00) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL30319828 | 0.84 | CDK5R1 (1.00) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL30319818 | 0.84 | GSK3B (0.83) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL30141665 | 0.81 | CDK5R1 (1.00) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL30309734 | 0.80 | CDK5R1 (1.00) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL29361130 | 0.78 | GSK3B (1.00) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL29924508 | 0.75 | GSK3B (0.72) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL30278941 | 0.74 | GSK3B (1.00) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL4064946 | 0.70 | CDK5 (0.60) | GSK3BCDK5R1CDK5GSK3ACDK1 | |
| SCHEMBL668946 | 0.68 | AHR (0.64) | GSK3BCDK5R1CDK5GSK3ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240384232-A1 | CLINICAL-GRADE THERAPEUTIC PROGENITORS GENERATED FROM TANKYRASE/PARP-INHIBITED PLURIPOTENT STEM CELL BANKS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-11-21 | — | — | US | claimed |
| CN-117795059-A | Muscle cells differentiated from pluripotent cells, methods of production and uses thereof | 阿利夫农场公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2023147009-A1 | CLINICAL-GRADE THERAPEUTIC PROGENITORS GENERATED FROM TANKYRASE/PARP-INHIBITED PLURIPOTENT STEM CELL BANKS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023034720-A1 | COMPOSITIONS AND METHODS FOR CELL REPROGRAMMING | CORNELL UNIVERSITY (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4073235-A1 | IN VITRO EXPANSION OF DOPAMINERGIC SUBTYPE NEURONAL PROGENITORS DERIVED FROM PLURIPOTENT STEM CELLS | Wisconsin Alumni Research Foundation (US) | 2022-10-19 | — | — | EP | claimed |
| CN-115151633-A | In vitro expansion of pluripotent stem cell-derived dopaminergic subtype neuronal progenitor cells | 威斯康星校友研究基金会 | 2022-10-04 | — | — | CN | claimed |
| EP-4687928-A1 | GENERATION OF BRANCHING URETERIC BUD AND COLLECTING DUCT ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | The Brigham & Women's Hospital, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4608977-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | disclosed |
| CN-119997942-A | Compounds for the treatment of cancer | 埃维克斯塔生物公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4536806-A2 | GENERATION OF LUNG ORGANOIDS FROM PLURIPOTENT STEM CELLS AND USE THEREOF | The Trustees Of Columbia University In The City Of New York (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4473093-A1 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | The Brigham and Women's Hospital, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240384232-A1 | CLINICAL-GRADE THERAPEUTIC PROGENITORS GENERATED FROM TANKYRASE/PARP-INHIBITED PLURIPOTENT STEM CELL BANKS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-11-21 | — | — | US | disclosed |
| CN-115151633-A | In vitro expansion of pluripotent stem cell-derived dopaminergic subtype neuronal progenitor cells | 威斯康星校友研究基金会 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022144632-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | CRISPR THERAPEUTICS AG (CH) | 2022-07-07 | — | — | WO | disclosed |
| CN-114672451-A | Regeneration of functional pulmonary vascular bed | 通用医疗公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-108699513-B | Regeneration of functional pulmonary vascular bed | 通用医疗公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | GSK3B 42/4885CDK5R1 944/4885CDK5 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.